| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5956274 | Chest | 2012 | 9 Pages |
Abstract
Fondaparinux for 45 days does not appear to be cost-effective when treating patients with isolated SVT of the legs. A better value for money could be obtained in subgroups of patients with a higher incidence of VTE after SVT. Shorter durations of treatment should be further evaluated in future clinical studies.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Marc MD, Marc MD, Henri MD, David L. PharmD, PhD,